Preliminary Results from a Study of Sevacizumab in Chinese Patients with Metastatic Colorectal Cancer Resistant to Oxaliplatin-Based First-Line Chemotherapy.

Nong Xu,Junning Cao,Yanqiao Zhang,Yanhua Ding,Chenyu Mao

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e15530

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e15530 Background: The purpose of this study was to evaluate the safety, the maximum tolerated dose, the antitumor activity, and pharmacokinetics of sevacizumab in patients with mCRC resistant to oxaliplatin-based first-line chemotherapy. Methods: This is an open-label, multicenter, Phase 1b, dose-finding study. Adult patients aged 18-74 years old with mCRC, who had been previously treated with oxaliplatin-based chemotherapy were enrolled and received intravenous sevacizumab (3-5 mg/kg) and FOLFIRI every 14 days. Standard 3+3 design was used in the dose escalation phase. The DLTs assessments were based on the first 2 cycles. In the expansion phase, the number of patients of every dose group can be expanded to 8-12. The primary endpoint was safety and tolerability. The secondary endpoint included PK and tumor response. The study was originally designed to assess the doses of 3, 4, and 5 mg/kg. Since high frequency and severity of proteinuria in the patients treated with sevacizumab was observed, the protocol was amended in the expansion phase to add 2 additional dose groups (2mg/kg and 1mg/kg) and these two dose groups can be directly expanded to 8-12 patients. Results: Totally forty-nine (49) patients were enrolled (3mg/kg, n = 12, 4mg/kg, n = 12, 5mg/kg, n = 11, and 2mg/kg, n = 14). Median duration of therapy was 7.3 cycles (range, one to 26.5 cycles). Up to January 18, 2018, 3 patients of 2mg/kg dose group are still on treatment. Tumor response was assessed in 35 patients, in which 54% patients (19 patients) achieve PR. And the maximum response rate in one patient treated with 3mg/kg was 80%. There were 3 dose limiting toxicities observed, including neutropenia with fever, grade 3 hypertension and grade 3 proteinuria (the urine protein can’t be back to < 2g/24h). The most common adverse events (grade 3+) were neutropenia (41%), proteinuria (24.4%), leukopenia (22.4%), hypertension (20.4%) and diarrhea (16%). Conclusions: Preliminary results from this study showed good efficacy of sevacizumab in mCRC patients and the study also provide good insights of dose selection in future clinical development of sevacizumab. Clinical trial information: NCT02453464.